Research programme: dihydrophthalazine antifolates - Basilea Pharmaceutica

Drug Profile

Research programme: dihydrophthalazine antifolates - Basilea Pharmaceutica

Alternative Names: BAL0030543; BAL0030544; BAL0030545; BAL30543; BAL30544; BAL30545

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Basilea Pharmaceutica
  • Class Phthalazines
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Enterococcal infections; Staphylococcal infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Enterococcal-infections in Switzerland
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Staphylococcal-infections in Switzerland
  • 30 Apr 2009 Preclinical pharmacodynamics data in Staphylococcal infections released by Basilea Pharmaceutica
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top